Use of the Janssen (Johnson & Johnson) COVID-19 Vaccine: Updated Interim Recommendations from the Advisory Committee on Immunization Practices — United States, December 2021
Sara E. Oliver(Centers for Disease Control and Prevention), Matthew F. Daley(Kaiser Permanente), Tara C. Jatlaoui(National Center for Chronic Disease Prevention and Health Promotion), Oliver Brooks, Agam K. Rao, a cura di Luciano De Fiore, Allison Lale, Michelle M. Hughes(Centers for Disease Control and Prevention), Stephen C. Hadler(The Task Force for Global Health), Lauri E. Markowitz(Centers for Disease Control and Prevention), Tom T. Shimabukuro(Centers for Disease Control and Prevention), Evelyn Twentyman(Synaptic Research (United States)), Karen R. Broder(Centers for Disease Control and Prevention), Monica Godfrey, Grace M. Lee, H. Keipp Talbot(Marshfield Clinic), Beth P. Bell(Centers for Disease Control and Prevention), David K. Shay(National Center for Emerging and Zoonotic Infectious Diseases), Isaac See(Centers for Disease Control and Prevention), Melinda Wharton(Centers for Disease Control and Prevention), Veronica V. McNally, Megan Wallace(Centers for Disease Control and Prevention), Sarah Mbaeyi(National Center for Immunization and Respiratory Diseases), John R. Su(National Center for Emerging and Zoonotic Infectious Diseases)
Cited by 102
Related Papers
Quadrivalent Human Papillomavirus Vaccine: Recommendations of the Advisory Committee on Immunization Practices (ACIP)
|PsycEXTRA Dataset|2007|1.9k
Population-level impact and herd effects following the introduction of human papillomavirus vaccination programmes: updated systematic review and meta-analysis
|The Lancet|2019|1.3k